Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
HDAC Enzyme Activity Inhibition (In Vitro) from US Patent US20240208956: "1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME"
Assay data:46 Active, 46 Activity ≤ 1 µM, 46 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
In Vitro Assay from US Patent US20240150300: "S-CONFIGURATION-CONTAINING AMINO BENZAMIDE PYRIDAZINONE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF"
Assay data:22 Active, 22 Activity ≤ 1 µM, 22 Tested
IC50 Assay from US Patent US11890356: "HDAC6 inhibitors and imaging agents"
Assay data:18 Active, 16 Activity ≤ 1 µM, 18 Tested
In vivo protac activity at VHL/AR in human VCaP cells xenografted SCID mouse assessed as reduction in PSA protein level in tumor at 50 mg/kg, ip administered as single dose measured after 3 to 48 hrs Western blot analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Protac activity at VHL/AR in AR-positive human VCaP cells assessed as induction of androgen receptor degradation at 100 nM preincubated with proteasome inhibitor, MG132 for 2 hrs followed by compound addition and measured after 6 hrs by Western blot analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Protac activity at VHL/AR in AR-positive human VCaP cells assessed as induction of androgen receptor degradation at 100 nM preincubated with NEDD8 activating E1 enzyme inhibitor, MLN4924 for 2 hrs followed by compound addition and measured after 6 hrs by Western blot analysis
Protac activity at VHL/AR in AR-positive human VCaP cells assessed as induction of androgen receptor degradation at 100 nM preincubated with VHL ligand, (2S,4R)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)-N-((S)-3-(methylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)-3-oxopropyl)pyrrolidine-2-carboxamide for 2 hrs followed by compound addition and measured after 6 hrs by Western blot analysis
Protac activity at VHL/AR in AR-positive human VCaP cells assessed as induction of androgen receptor degradation at 100 nM preincubated with N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(2-hydroxyethyl)-1H-pyrazole-4-carboxamide for 2 hrs followed by compound addition and measured after 6 hrs by Western blot analysis
Protac activity at VHL/AR in AR-positive human LNCaP cells assessed as induction of androgen receptor degradation at 100 nM preincubated with proteasome inhibitor, MG132 for 2 hrs followed by compound addition and measured after 6 hrs by Western blot analysis
Protac activity at VHL/AR in AR-positive human LNCaP cells assessed as induction of androgen receptor degradation at 100 nM preincubated with NEDD8 activating E1 enzyme inhibitor, MLN4924 for 2 hrs followed by compound addition and measured after 6 hrs by Western blot analysis
Protac activity at VHL/AR in AR-positive human LNCaP cells assessed as induction of androgen receptor degradation at 100 nM preincubated with VHL ligand, (2S,4R)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)-N-((S)-3-(methylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)-3-oxopropyl)pyrrolidine-2-carboxamide for 2 hrs followed by compound addition and measured after 6 hrs by Western blot analysis
Protac activity at VHL/AR in AR-positive human LNCaP cells assessed as induction of androgen receptor degradation at 100 nM preincubated with N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(2-hydroxyethyl)-1H-pyrazole-4-carboxamide for 2 hrs followed by compound addition and measured after 6 hrs by Western blot analysis
Protac activity at VHL/AR in human VCaP cells assessed as induction of protein degradation at 10 nM measured after 24 hrs by Western blot analysis relative to control
Protac activity at VHL/AR in human 22Rv1 cells assessed as induction of protein degradation measured after 24 hrs by Western blot analysis
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Protac activity at VHL/AR in human VCaP cells assessed as induction of protein degradation measured after 24 hrs by Western blot analysis
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
Protac activity at VHL/AR in human LNCaP cells assessed as induction of protein degradation measured after 24 hrs by Western blot analysis
Protac activity at VHL/AR in AR-positive human VCaP cells assessed as reduction in protein level at 100 nM measured after 2 to 4 hrs by Western blot analysis
Protac activity at VHL/AR in AR-positive human LNCaP cells assessed as reduction in protein level at 100 nM measured after 2 to 4 hrs by Western blot analysis
Binding affinity to VHL (unknown origin) incubated for 60 mins by FP based binding assay
Assay data:8 Active, 8 Activity ≤ 1 µM, 8 Tested
Protac activity at VHL/AR in AR-positive human LNCaP cells assessed as induction of androgen receptor degradation at 10 uM incubated for 6 hrs by Western blot analysis (Rvb = 0%)
Assay data:15 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on